Lisa Astor | Authors

January 17, 2021

When compared with standard capecitabine and bevacizumab therapy, patients with unresectable metastatic colorectal cancer saw an increase in overall and progression-free survival.

January 15, 2021

Patient's surgical risk for potentially resectable advanced thoracic esophageal cancer is not negatively impacted by neoadjuvant chemotherapy, study finds.

December 10, 2020

Final data from a phase 2 trial suggested that the administration of trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

December 07, 2020

TNB-383B was well tolerated and researchers saw significant responses when it was administered at a higher dose level for heavily pretreated patients with relapsed/refractory multiple myeloma.

December 06, 2020

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

December 04, 2020

The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.

December 04, 2020

A phase 1 trial showed that treatment with neoadjuvant nivolumab was tolerable in patients with nonmetastatic high-risk clear cell renal cell carcinoma.

September 21, 2020

Findings from the phase 2 FLIPPER trial indicated that frontline fulvestrant (Faslodex) in combination with palbociclib (Ibrance) demonstrated an improvement in PFS at 1 year in patients with endocrine-sensitive HR-positive, HER2-negative metastatic breast cancer.

June 04, 2020

Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.